TP53-related clonal competition and disrupted molecular processes in CLL

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F24%3A00137827" target="_blank" >RIV/00216224:14740/24:00137827 - isvavai.cz</a>
Result on the web
<a href="https://ericll2024.org/" target="_blank" >https://ericll2024.org/</a>
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
TP53-related clonal competition and disrupted molecular processes in CLL
Original language description
The presence of either TP53 gene loss or mutation defined high-risk CLL especially in the era of chemoimmunotherapy. Its prognostic and predictive impact remains a matter of debate in the setting of BTKi- and BCL2i-based treatment, which does not act directly via the TP53 pathway, but yet seems to associate with worse clinical outcomes. The adverse effect on overall survival, at least upon chemoimmunotherapy, is notable not only in patients with expanded but also in lowburden TP53 mutations, which were identified in 5–35% of CLL patients. In this study, we aimed to scrutinize the principles of clonal competition in CLL and identify factors influencing the development of TP53-mutated subclones in various clinical contexts.
Czech name
—
Czech description
—

Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)